Search research articles
Contact Us
Filters
Showing results (221-230 of 248) with videos related to
Page
of 25
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 24, 2024
Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial
Charles B Nguyen, Melissa A Reimers, Chamila Perera, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
March 26, 2020
CD8<sup>+</sup> T Cells Impact Rising PSA in Biochemically Relapsed Cancer Patients Using Immunotherapy Targeting Tumor-Associated Antigens
Neal D Shore, Matthew P Morrow, Trevor McMullan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 9, 2017
Muscadine Grape Skin Extract (MPX) in Men with Biochemically Recurrent Prostate Cancer: A Randomized, Multicenter, Placebo-Controlled Clinical Trial
Channing J Paller, Xian C Zhou, Elisabeth I Heath, et al.
Prostate Cancer and Prostatic Diseases
|
August 12, 2025
Correction: Natural killer cell infiltration in prostate cancers predict improved patient outcomes
Nicholas A Zorko, Allison Makovec, Andrew Elliott, et al.
Cancer Immunology Research
|
February 21, 2025
Inhibition of PIM Kinase in Tumor-Associated Macrophages Suppresses Inflammasome Activation and Sensitizes Prostate Cancer to Immunotherapy
Amber N Clements, Andrea L Casillas, Caitlyn E Flores, et al.
Prostate Cancer and Prostatic Diseases
|
February 28, 2024
Natural Killer Cell Infiltration in Prostate Cancers Predict Improved Patient Outcomes
Nicholas A Zorko, Allison Makovec, Andrew Elliott, et al.
Journal for Immunotherapy of Cancer
|
June 29, 2023
Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomas
Andrew L Coveler, David C Smith, Tycel Phillips, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 1, 2023
Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes
Justin Hwang, Xiaolei Shi, Andrew Elliott, et al.
BMC Cancer
|
June 15, 2019
A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA)
Roche Kapoor, Matthew P Deek, Riley McIntyre, et al.
JCO Oncology Practice
|
December 19, 2024
Implementation of Universal Germline Genetic Testing Into Standard of Care for Patients With Prostate Cancer: The Time Is Now
Neal Shore, Sarah M Nielsen, Edward D Esplin, et al.
Page
of 25
Search research articles
Search
Showing results (221-230 of 248) with videos related to
Sort By:
Page
of 25
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 24, 2024
Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial
Charles B Nguyen, Melissa A Reimers, Chamila Perera, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
March 26, 2020
CD8<sup>+</sup> T Cells Impact Rising PSA in Biochemically Relapsed Cancer Patients Using Immunotherapy Targeting Tumor-Associated Antigens
Neal D Shore, Matthew P Morrow, Trevor McMullan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 9, 2017
Muscadine Grape Skin Extract (MPX) in Men with Biochemically Recurrent Prostate Cancer: A Randomized, Multicenter, Placebo-Controlled Clinical Trial
Channing J Paller, Xian C Zhou, Elisabeth I Heath, et al.
Prostate Cancer and Prostatic Diseases
|
August 12, 2025
Correction: Natural killer cell infiltration in prostate cancers predict improved patient outcomes
Nicholas A Zorko, Allison Makovec, Andrew Elliott, et al.
Cancer Immunology Research
|
February 21, 2025
Inhibition of PIM Kinase in Tumor-Associated Macrophages Suppresses Inflammasome Activation and Sensitizes Prostate Cancer to Immunotherapy
Amber N Clements, Andrea L Casillas, Caitlyn E Flores, et al.
Prostate Cancer and Prostatic Diseases
|
February 28, 2024
Natural Killer Cell Infiltration in Prostate Cancers Predict Improved Patient Outcomes
Nicholas A Zorko, Allison Makovec, Andrew Elliott, et al.
Journal for Immunotherapy of Cancer
|
June 29, 2023
Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomas
Andrew L Coveler, David C Smith, Tycel Phillips, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 1, 2023
Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes
Justin Hwang, Xiaolei Shi, Andrew Elliott, et al.
BMC Cancer
|
June 15, 2019
A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA)
Roche Kapoor, Matthew P Deek, Riley McIntyre, et al.
JCO Oncology Practice
|
December 19, 2024
Implementation of Universal Germline Genetic Testing Into Standard of Care for Patients With Prostate Cancer: The Time Is Now
Neal Shore, Sarah M Nielsen, Edward D Esplin, et al.
Page
of 25